| Item Type | Name |
|
Concept
|
Antibodies, Bacterial
|
|
Concept
|
Antibodies, Viral
|
|
Concept
|
Antibodies, Monoclonal
|
|
Concept
|
Antibodies, Monoclonal, Humanized
|
|
Concept
|
Antibodies
|
|
Academic Article
|
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.
|
|
Academic Article
|
Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data.
|
|
Academic Article
|
Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial.
|
|
Academic Article
|
Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease.
|
|
Academic Article
|
A practical, evidence-based guide to the use of adalimumab in Crohn's disease.
|
|
Academic Article
|
Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center.
|
|
Academic Article
|
Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
|
|
Academic Article
|
Serum adalimumab concentration and clinical remission in patients with Crohn's disease.
|
|
Academic Article
|
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center.
|
|
Academic Article
|
Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.
|
|
Academic Article
|
Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease.
|
|
Academic Article
|
Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease.
|
|
Academic Article
|
Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis.
|
|
Academic Article
|
Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy.
|
|
Academic Article
|
Vedolizumab in the treatment of Crohn's disease.
|
|
Academic Article
|
Safety and Efficacy of Live Measles Vaccine Administered to a Crohn's Disease Patient Receiving Vedolizumab.
|
|
Academic Article
|
Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.
|
|
Academic Article
|
Many Inflammatory Bowel Disease Patients Are Not Immune to Measles or Pertussis.
|
|
Academic Article
|
Long-term Efficacy of Vedolizumab for Ulcerative Colitis.
|
|
Academic Article
|
Long-term Efficacy of Vedolizumab for Crohn's Disease.
|
|
Academic Article
|
Detection of adalimumab and antibodies to adalimumab using a homogeneous mobility shift assay.
|
|
Academic Article
|
Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
|
|
Academic Article
|
The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions.
|
|
Academic Article
|
Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.
|
|
Academic Article
|
Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety.
|
|
Academic Article
|
Emerging Therapies for Inflammatory Bowel Disease.
|
|
Academic Article
|
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.
|
|
Academic Article
|
The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease.
|
|
Academic Article
|
Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials.
|
|
Academic Article
|
Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab.
|
|
Academic Article
|
Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2.
|
|
Academic Article
|
Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply.
|
|
Academic Article
|
Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial.
|
|
Academic Article
|
The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know?
|
|
Academic Article
|
Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
|
|
Academic Article
|
Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis.
|
|
Academic Article
|
Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis.
|
|
Academic Article
|
Emerging treatment options for extraintestinal manifestations in IBD.
|
|
Academic Article
|
Long-term safety of vedolizumab for inflammatory bowel disease.
|
|
Academic Article
|
Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis.
|
|
Academic Article
|
Vedolizumab and Anti-Tumour Necrosis Factor a Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study.
|
|
Academic Article
|
Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease.
|
|
Academic Article
|
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
|
|
Academic Article
|
A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab.
|
|
Academic Article
|
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.
|
|
Academic Article
|
IL-23 Monoclonal Antibodies for IBD: So Many, So Different?
|
|
Academic Article
|
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
|
|
Academic Article
|
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
|
|
Academic Article
|
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
|
|
Academic Article
|
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
|